接受b/tsDMARD单药治疗与联合甲氨蝶呤治疗的PsA患者临床参数及药物留存率无差异:来自RABBIT-SpA登记处的数据
两组基线临床 domains 相似,仅联合组对既往治疗耐受性满意度显著更优;药物留存率无差异(p=0.4)。
要点
- PsA患者起始b/tsDMARD时69%用单药、31%联合MTX。
- 两组基线皮肤、甲、关节、指炎、附着点炎及中轴受累相似。
- 药物留存率无差异(p=0.4),6/12个月单药组66%/48%、联合组67%/48%仍在原治疗。
核心结论
- 未发现任何临床参数对PsA患者选择b/tsDMARD单药或联合MTX治疗有显著影响。
- 单药与联合治疗的药物留存率相似。
- 起始b/tsDMARD时继续MTX的决定似乎主要基于对MTX治疗的主观耐受性。
研究设计与样本
- RABBIT-SpA为前瞻性纵向队列研究,纳入axSpA和PsA患者。
- 本分析将PsA患者分为起始b/tsDMARD单药组(n=900,69%)和联合MTX组(n=405,31%)。
- 采用药物生存分析比较治疗留存率。
主要发现
- 基线时两组皮肤、甲、关节受累、指炎、附着点炎及中轴受累等临床 domains 相似。
- 仅联合组在治疗开始时对既往治疗耐受性的满意度显著更优。
- 两组药物留存率无差异(p=0.4)。
- 6个月时单药组66%、联合组67%仍在原治疗;12个月时两组均为48%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The potential benefit of methotrexate (MTX) in combination with biologic (b) and targeted synthetic (ts) disease modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) is still a matter of debate. OBJECTIVES: To compare clinical and patient reported characteristics as well as drug retention rates in PsA patients receiving b/tsDMARD monotherapy or in combination with MTX. METHODS: RABBIT-SpA is a prospective longitudinal cohort study including axSpA and PsA patients. In this analysis, PsA patients were stratified into two groups: starting b/tsDMARD as monotherapy or in combination with MTX. Treatment retention was compared by drug survival analysis. RESULTS: 69% of the patients (n=900) started b/tsDMARD as monotherapy while 31% were treated in combination with MTX (n=405). At baseline, clinical domains like skin, nail and joint affection, dactylitis, enthesitis and axial involvement were similar between the groups. Only the patients' satisfaction concerning tolerability of the previous treatment was significantly better in the combination group at treatment start. Drug retention rates did not differ between the groups (p=0.4). At 6/12 months, 66%/48% of patients in monotherapy and 67%/48% in the combination group were still on their original treatment. CONCLUSIONS: We did not identify any clinical parameters with notable influence on the choice of b/tsDMARD mono or MTX-combination therapy in PsA. Drug retention rates are similar between mono and combination therapy. It seems that the decision to continue MTX at initiation of b/tsDMARDs is mostly based on the subjective tolerability of MTX treatment.
引用
- Regierer AC, Kiefer D, Schett G, et al. No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry. RMD Open. 2024. PMID: 39043613. doi:10.1136/rmdopen-2024-004389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。